Good Science but Poor Management (Favoritism and Nepotism is Rampant) - Recensione dipendente - Senior Scientist presso Merck

2,0
4 nov 2018
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Good science, lot of projects to work on and promising portfolio.

Svantaggi

Many re-orgs this year. Good people at management level are leaving and people with little or no management skills are given their positions. Favoritism and Nepotism is very rampant - can be seen in who they hire, who is given promotion and who gets the "most visible" projects. Lack of innovation and some projects seem redundant with unnecessary more stress on resources.

Esplora altre recensioni su Merck

5,0
3 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

End of the year shutdown which includes paid time off

Svantaggi

The con for me at the time was that I had to relocate which wasn’t possible

4,0
2 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Over my tenure, I had the opportunity to work alongside highly talented and mission-driven colleagues dedicated to improving patient outcomes. The organization provided exposure to cross-functional collaboration, leadership development opportunities, and meaningful work supporting healthcare providers, patients, and community stakeholders. I appreciated the company's commitment to innovation, professional growth, and serving patients through scientific advancement.

Svantaggi

Like many large organizations, priorities and organizational structures evolved over time, which occasionally created uncertainty and changes in responsibilities. Decision-making processes could sometimes be complex due to the size of the organization, and navigating multiple layers of stakeholders occasionally impacted speed and execution.

Vedi recensioni per: Utile|Valutazione|Data|Tutto